AWM
NVCR icon

Accel Wealth Management’s NovoCure NVCR Stock Holding History

Accel Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-85
Closed -$7K – 1082
2022
Q3 		$7K Hold
85
– – ﹤0.01% 802
2022
Q2 		$6K Hold
85
– – ﹤0.01% 789
2022
Q1 		$7K Hold
85
– – ﹤0.01% 764
2021
Q4 		$6K Buy
+85
New +$8.53K ﹤0.01% 789

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Accel Wealth Management's NVCR Position: Q4 2022 in Review

Accel Wealth Management sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 85 shares — an estimated $7K sold.

Accel Wealth Management first reported a position in NVCR in Q4 2021 and held it in 4 quarters. The position peaked at $7K in Q3 2022. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Accel Wealth Management reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Accel Wealth Management sold 85 NovoCure shares in Q4 2022, an estimated $7K.
  • Accel Wealth Management first reported a position in NovoCure in Q4 2021 and held it in 4 quarters.
  • Accel Wealth Management's NovoCure position peaked at $7K in Q3 2022.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Accel Wealth Management's 13F filing for Q4 2022, filed 26 Jan 2023.